Stocks · News reference

UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27

Oct 12, 2026, 1:43 PMBenzinga Newsdesk

UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 12, 2026, 1:43 PM
Checked: Oct 12, 2026, 1:43 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 12, 2026, 12:03 PMBenzinga Newsdesk
Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
ODTX
BenzingaOct 9, 2026, 1:05 PMBenzinga Newsdesk
Odyssey Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $42 price target.
ODTX
BenzingaOct 9, 2026, 11:01 AMBenzinga Newsdesk
Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42
ODTX